AstraZeneca Plc’s breast-cancer pill trial failure could trim several billion dollars from the drug’s potential sales, according to analysts, Bloomberg reported.
Article
AstraZeneca Breast-Cancer Pill Trial Miss May Cut Sales by Billions
--・
Disclaimer: Includes third-party opinions. No advice. Binance AI may be used without guarantee. See T&Cs.
AZNUS+0.89%